Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million, significantly beating analyst estimates despite an 11% year-over-year total revenue decline caused by the timing of milestone payments. The company achieved a major financial milestone by reaching total company profitability ahead of schedule, supported by a 46% increase in clonoSEQ test volumes and disciplined expense management.
Key Highlights
- Core MRD revenue reached $72.6 million, representing 44% year-over-year growth when excluding milestone payments.
- clonoSEQ test volume surged to 39,587 tests, a 46% increase compared to the third quarter of 2025.
- GAAP net income turned positive at $2.8 million, or $0.02 per diluted share, compared to a net loss of $24.2 million in the prior year excluding specific agreement revenue.
- Management raised full-year 2026 MRD revenue guidance to between $276 million and $286 million, up from the previous range of $268 million to $278 million.